☞ On deadline? For media inquiries CLICK HERE.
October 14-17: ISTX24: PCCA International Seminar, Houston
October 22: APC webinar with Pharmacists Mutual: Coverage, Claims, and Compounding: What You Need to Know About Your Liability Insurance
October 29: PCAC meeting on adding several bulk drug substances to the 503A Bulks List (1 of 2)
November 7: APC webinar: Preservatives in Pharmacy Compounding
November 15-17: Personalized Medicine Certification Course 1: Endocrinology in St. Pete Beach, Fla.
December 4: PCAC meeting on adding several bulk drug substances to the 503A Bulks List (2 of 2)
December 13: APC Board of Directors Meeting, Las Vegas
December 13-15: A4M Longevity Fest, Las Vegas
Specialty Pharmacy Continuum has a great piece on the importance of a longer "tail" for 503As.
This time Wired missed the mark on pharmacy compounding, but it at least quoted Scott and focused on the important issues.
Wired looks at how some patients are being hit hard by tirzepatide coming off shortage.
It could have chosen any angle, and it went with the high price of commercial versions. 👍🏻
The article, which of course quotes APC, focuses on the impact on patients of tirzepatide coming out of shortage.
Medscape is the latest news outlet to cover tirzepatide, and it focuses on APC's perspective.
Since the FDA announced that tirzepatide is (for now) out of shortage, APC's Scott Brunner has been all over the news offering our perspective.
Baseless but time-consuming lawsuit threats make compounders shy.
The piece spends a lot of time considering misconceptions about compounded GLP-1s, but it least it included a little straight info from Scott.
Scott tells Medscape that actually helping patients with vial-based tirzepatide is a welcome change for Lilly.
"It is absolutely intentional policy on the part of FDA."